Cardiac PET

Cardiac positron emission tomography (PET) is a nuclear imaging modality that can show heart cell metabolism that reveals areas of ischemia or infarct where this low or no blood flow due to coronary artery disease and myocardial infarction. PET can help determine in if areas of the heart effected by a heart attack can be reversed through revascularization. PET can also offer additional information on the patient's condition with myocardial flow reserve (MFR) information. Cardiac PET uses a rubidium (Rb-82) radiotracer injection, which only has a half life of 75 seconds, which greatly speeds scan times compared to traditional cardiac SPECT imaging.

RSS icon
Positron NeuSight PET-CT 64 slice scanner

Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

GE HealthCare Omni Legend PET/CT scanner production North America United States

GE HealthCare moves PET/CT scanner production to United States

The all-in-one Omni Legend PET/CT scanner is now being manufactured in a new production facility in Waukesha, Wisconsin.

Georgia Lawrence, JD, with ASNC, explains how CMS uses hospital reported data to develop cardiac PET payment rates.

Understanding hospital billing for cardiac PET/CT

Significant fluctuations in PET and CT reimbursement rates have made it especially challenging to keep up with this complex topic. We spoke to an expert to learn more.

Erin Stevens explained the technical aspects for a successful PET program. #ASNC #thinkPET

Key steps to implementing a successful PET program

Getting technologists, physicians and administrators to work together is a crucial part of any PET program. Research is also essential. Cardiovascular Business spoke to a specialist on the topic to learn more.

The new cardiac PET radiotracer flurpiridaz F-18 is posed to be a major game changer and will likely lead to increased adoption of cardiac PET.

FDA approves GE HealthCare's flurpiridaz F-18 PET radiotracer for CAD

The newly approved radiotracer is seen as a major step forward for nuclear imaging technology. Specialists have been looking forward to its arrival on the market for quite some time.

Erin R. Stevens, CNMT, NCT, director of nuclear medicine at Oregon Heart Center, said training physicians for what is needed in cardiac PET documentation is key for preventing issues with prior authorizations. ASNC photo

Good documentation is the key to cardiac PET prior authorizations

Knowing what, exactly, is needed in cardiac PET documentation is one of the best ways to limit prior authorization issues.

Cardiac PET on the rise among U.S. cardiologists

SPECT is still the most common modality used to evaluate CAD patients, but cardiac PET is gaining more and more momentum.

Displaying 1 - 8 of 33
Design by Adaptive Theme